NasdaqHealth CarePharmaceutical PreparationsHERZLIYA, IsraelPrimary ticker: NRSN

NeuroSense Therapeutics Ltd. NRSNW

NRSNW is a NeuroSense Therapeutics Ltd. warrant listed on Nasdaq. Its price is shown below; holders, insider trades and filings are for the company. The company’s common stock is NRSN →

CIK 1875091

Insider trades, 12 mo

2 buys · 0 sells

$400.0K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

10.1% of shares · 0 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in NeuroSense Therapeutics Ltd.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

2 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 16, 2026. Insiders have two business days to file.

Recent insider trades

Alon Ben-Noon Chief Executive Officer	Jun 16 Form 4 ↗	Buy	+$200.0K 250,000 sh @ $0.80	-88.4%
Or Eisenberg Chief Financial Officer	Jun 16 Form 4 ↗	Buy	+$200.0K 250,000 sh @ $0.80	-88.4%

All NRSNW insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

164,650 shares

3 funds report NRSNW. Values checked against market prices.

Reports for the quarter ending Sep 30, 2026 are still coming in (1 position so far, against 3 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 0 new, 0 added to, 1 trimmed, 0 exited since Q1 2026.

Top 13F holders
#
1	Empery Asset Management, LP 13F ↗	100,402	$6,325	unchanged
2	Clear Street Group Inc. 13F ↗	63,085	$3,974	-0.5%
3	UBS Group AG 13F ↗	1,163	$73	unchanged

Download CSV Every fund that holds NRSNW, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What NeuroSense Therapeutics Ltd. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What NeuroSense Therapeutics Ltd. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2021	5	—	806,097	$605.0K
Q1 2022	4	-1	374,134	$224.0K
Q2 2022	4	0	439,558	$229.0K
Q3 2022	5	+1	450,361	$109.0K
Q4 2022	4	-1	287,262	$53.5K
Q1 2023	4	0	467,047	$152.1K
Q2 2023	5	+1	262,149	$59.0K
Q3 2023	6	+1	324,477	$50.3K
Q4 2023	3	-3	209,527	$18.3K
Q1 2024	4	+1	235,469	$98.9K
Q2 2024	4	0	121,347	$25.0K
Q3 2024	4	0	111,434	$17.1K
Q4 2024	4	0	106,400	$43.9K
Q1 2025	3	-1	78,600	$16.1K
Q2 2025	2	-1	65,155	$41.3K
Q3 2025	2	0	64,965	$24.6K
Q4 2025	3	+1	164,950	$56.7K
Q1 2026	3	0	164,950	$32.8K
Q2 2026	3	0	164,650	$10.4K
Q3 2026	1	-2	1,163	$52

Each point is a quarter-end, from Q4 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (M74240116). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakesNone in 12 mo 8-K eventsNone in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: NeuroSense Therapeutics Ltd.
Address: 11 HAMENOFIM ST., BUILDING B, HERZLIYA, Israel 4672562
Phone: 972-9-9531142
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, emerging growth company
Incorporated in: Israel
Listed as: NRSN (Nasdaq), NRSNW (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

Price of NRSNW, not of the company’s common stock

$0.0055−$0.00 (−1.79%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.0053 · High $0.0129Nov 13, 2026

Aug 13, 2026Low $0.0053 · High $0.1187Nov 13, 2026

Nov 13, 2025Low $0.0053 · High $0.4199Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.